Pharmacogenetics: optimising prescribing in primary care

Prescriber, vol. 33, pp. 10–13

Abstract

Pharmacogenetic (PGx) testing to personalise prescribing of certain medicines can improve patient outcomes and reduce adverse drug reactions. This article summarises the key findings of the PGx Impact study, designed to estimate the impact of pre‐emptive genetic testing on prescribing, and discusses potential ways in which pharmacogenetic testing may optimise primary care prescribing in the near future.

Authors 4

1. Essra Youssef

   University of East Anglia · Norwich Research Park

   Affiliation as printed

   Essra Youssef is a Research Pharmacist, School of Pharmacy, University of East Anglia, Norwich Research Park

2. Tracey Thornley

   University of Nottingham

   Affiliation as printed

   Tracey Thornley is an Honorary Professor in Pharmacy Practice, School of Pharmacy, University of Nottingham

3. Henk‐Jan Guchelaar Aachen Henk‐Jan Guchelaar is Professor of Clinical Pharmacy Department of Clinical Pharmacy and Toxicology

   Leiden University Medical Center

   Affiliation as printed

   Henk‐Jan Guchelaar is Professor of Clinical Pharmacy, Department of Clinical Pharmacy and Toxicology, Leiden University Medical Center

   Henk-Jan Guchelaar is Professor of Clinical Pharmacy, Department of Clinical Pharmacy and Toxicology, Leiden University Medical Center

4. David John Wright

   University of Leicester

   Affiliation as printed

   David J Wright is Professor of Health Services Research, School of Allied Health Professions, University of Leicester